S&P 500   4,291.37 (-0.13%)
DOW   33,928.83 (+0.05%)
QQQ   332.02 (-0.31%)
AAPL   172.53 (-0.38%)
MSFT   292.07 (-0.48%)
META   179.33 (-0.86%)
GOOGL   121.95 (-0.11%)
AMZN   144.00 (+0.57%)
TSLA   937.15 (+0.99%)
NVDA   189.48 (-0.44%)
NIO   21.05 (-1.17%)
BABA   91.99 (-2.35%)
AMD   100.98 (-0.03%)
MU   64.17 (-0.82%)
T   18.41 (+0.11%)
CGC   3.75 (-1.83%)
F   16.31 (-0.06%)
GE   79.75 (-0.08%)
DIS   124.07 (-0.15%)
AMC   24.95 (+3.06%)
PYPL   101.63 (+0.12%)
PFE   49.61 (-0.28%)
NFLX   247.60 (-0.61%)
S&P 500   4,291.37 (-0.13%)
DOW   33,928.83 (+0.05%)
QQQ   332.02 (-0.31%)
AAPL   172.53 (-0.38%)
MSFT   292.07 (-0.48%)
META   179.33 (-0.86%)
GOOGL   121.95 (-0.11%)
AMZN   144.00 (+0.57%)
TSLA   937.15 (+0.99%)
NVDA   189.48 (-0.44%)
NIO   21.05 (-1.17%)
BABA   91.99 (-2.35%)
AMD   100.98 (-0.03%)
MU   64.17 (-0.82%)
T   18.41 (+0.11%)
CGC   3.75 (-1.83%)
F   16.31 (-0.06%)
GE   79.75 (-0.08%)
DIS   124.07 (-0.15%)
AMC   24.95 (+3.06%)
PYPL   101.63 (+0.12%)
PFE   49.61 (-0.28%)
NFLX   247.60 (-0.61%)
S&P 500   4,291.37 (-0.13%)
DOW   33,928.83 (+0.05%)
QQQ   332.02 (-0.31%)
AAPL   172.53 (-0.38%)
MSFT   292.07 (-0.48%)
META   179.33 (-0.86%)
GOOGL   121.95 (-0.11%)
AMZN   144.00 (+0.57%)
TSLA   937.15 (+0.99%)
NVDA   189.48 (-0.44%)
NIO   21.05 (-1.17%)
BABA   91.99 (-2.35%)
AMD   100.98 (-0.03%)
MU   64.17 (-0.82%)
T   18.41 (+0.11%)
CGC   3.75 (-1.83%)
F   16.31 (-0.06%)
GE   79.75 (-0.08%)
DIS   124.07 (-0.15%)
AMC   24.95 (+3.06%)
PYPL   101.63 (+0.12%)
PFE   49.61 (-0.28%)
NFLX   247.60 (-0.61%)
S&P 500   4,291.37 (-0.13%)
DOW   33,928.83 (+0.05%)
QQQ   332.02 (-0.31%)
AAPL   172.53 (-0.38%)
MSFT   292.07 (-0.48%)
META   179.33 (-0.86%)
GOOGL   121.95 (-0.11%)
AMZN   144.00 (+0.57%)
TSLA   937.15 (+0.99%)
NVDA   189.48 (-0.44%)
NIO   21.05 (-1.17%)
BABA   91.99 (-2.35%)
AMD   100.98 (-0.03%)
MU   64.17 (-0.82%)
T   18.41 (+0.11%)
CGC   3.75 (-1.83%)
F   16.31 (-0.06%)
GE   79.75 (-0.08%)
DIS   124.07 (-0.15%)
AMC   24.95 (+3.06%)
PYPL   101.63 (+0.12%)
PFE   49.61 (-0.28%)
NFLX   247.60 (-0.61%)
NASDAQ:AVDL

Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News

$6.89
+0.02 (+0.29%)
(As of 08/16/2022 09:35 AM ET)
Add
Compare
Today's Range
$6.85
$6.90
50-Day Range
$2.20
$7.31
52-Week Range
$1.05
$11.59
Volume
208 shs
Average Volume
805,115 shs
Market Capitalization
$406.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.29

Avadel Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
49.7% Upside
$10.29 Price Target
Short Interest
Healthy
8.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.65mentions of Avadel Pharmaceuticals in the last 14 days
Based on 36 Articles This Week
Insider Trading
Acquiring Shares
$155,400 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.76) to ($0.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

146th out of 1,124 stocks

Pharmaceutical Preparations Industry

57th out of 555 stocks

AVDL stock logo

About Avadel Pharmaceuticals (NASDAQ:AVDL) Stock

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals Stock Performance

Shares of Avadel Pharmaceuticals stock traded down $0.06 on Monday, hitting $6.87. 617,734 shares of the company traded hands, compared to its average volume of 1,976,978. The firm's 50-day simple moving average is $3.91 and its 200 day simple moving average is $5.21. The company has a debt-to-equity ratio of 2.11, a quick ratio of 2.72 and a current ratio of 2.72. Avadel Pharmaceuticals has a 12-month low of $1.05 and a 12-month high of $11.59.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.60). During the same quarter in the previous year, the firm posted ($0.33) EPS. On average, analysts expect that Avadel Pharmaceuticals will post -1.76 EPS for the current year.

Analysts Set New Price Targets

AVDL has been the topic of several recent analyst reports. Jefferies Financial Group cut shares of Avadel Pharmaceuticals from a "buy" rating to a "hold" rating and increased their target price for the stock from $6.00 to $8.00 in a research note on Wednesday, August 10th. Needham & Company LLC increased their target price on shares of Avadel Pharmaceuticals from $6.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, August 10th. SVB Leerink increased their target price on shares of Avadel Pharmaceuticals from $6.00 to $12.00 and gave the stock an "outperform" rating in a research note on Thursday. Craig Hallum lowered their target price on shares of Avadel Pharmaceuticals from $15.50 to $12.00 and set a "buy" rating on the stock in a research note on Thursday, July 28th. Finally, Stifel Nicolaus increased their target price on shares of Avadel Pharmaceuticals from $2.00 to $5.00 in a research note on Tuesday, July 19th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $10.29.

Insider Buying and Selling

In other Avadel Pharmaceuticals news, CFO Thomas S. Mchugh bought 50,000 shares of the firm's stock in a transaction that occurred on Friday, May 27th. The shares were bought at an average price of $2.14 per share, for a total transaction of $107,000.00. Following the transaction, the chief financial officer now directly owns 71,500 shares in the company, valued at $153,010. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Avadel Pharmaceuticals news, Director Eric J. Ende bought 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 31st. The shares were bought at an average price of $2.16 per share, for a total transaction of $32,400.00. Following the transaction, the director now directly owns 114,900 shares in the company, valued at $248,184. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Thomas S. Mchugh bought 50,000 shares of the firm's stock in a transaction that occurred on Friday, May 27th. The stock was acquired at an average price of $2.14 per share, for a total transaction of $107,000.00. Following the transaction, the chief financial officer now owns 71,500 shares in the company, valued at $153,010. The disclosure for this purchase can be found here. Insiders have acquired a total of 75,000 shares of company stock worth $155,400 in the last 90 days. 3.20% of the stock is owned by company insiders.

Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Stock News Headlines

Want To Catch The Next Hot Investing Trend (Look Inside?)
While millennials are trying to get rich in crypto Ponzi schemes- there's something happening that Wall Street is TOTALLY ignoring. And it's about to affect every American Citizen over 55...
What 5 Analyst Ratings Have To Say About Avadel Pharmaceuticals
Copper Exploration Heating Up
Canada is already known as a miner's paradise. But British Columbia (BC) is quietly becoming the new copper hotspot. That's because copper is critical to the world's shift to renewable energy. Biden earmarked $226 billion in new infrastructure projects all requiring copper.
Avadel Pharmaceuticals Provides Corporate Update
See More Headlines
Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Company Calendar

Last Earnings
8/09/2022
Today
8/16/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVDL
Employees
66
Year Founded
2015

Price Target and Rating

Average Stock Price Forecast
$10.29
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+49.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-77,330,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$22.33 million
Book Value
$1.33 per share

Miscellaneous

Free Float
57,149,000
Market Cap
$406.79 million
Optionable
Optionable
Beta
1.51

Social Links


Key Executives

  • Mr. Gregory J. Divis Jr. (Age 55)
    CEO & Director
    Comp: $862.59k
  • Mr. Thomas S. McHugh (Age 57)
    Sr. VP & CFO
    Comp: $550k
  • Mr. Richard Kim (Age 53)
    Chief Commercial Officer
    Comp: $596.3k
  • Mr. Jerad G. Seurer
    Gen. Counsel & Company Sec.
  • Mr. Gregory J. Davis (Age 57)
    VP of Corp. and Bus. Devel.
  • Mr. Mark W. Elrod
    VP of Sales
  • Ms. Angie Woods
    VP of People & Culture
  • Mr. Christian Kalita Pharm.D
    Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs
  • Mr. Steven G. Sullivan (Age 57)
    VP of Sales & Marketing and Head of Commercial Operations
  • Dr. Jordan S. Dubow M.D. (Age 44)
    Consultant













AVDL Stock - Frequently Asked Questions

Should I buy or sell Avadel Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings
or view top-rated stocks.

What is Avadel Pharmaceuticals' stock price forecast for 2022?

6 equities research analysts have issued 1-year target prices for Avadel Pharmaceuticals' shares. Their AVDL share price forecasts range from $5.00 to $13.00. On average, they predict the company's share price to reach $10.29 in the next twelve months. This suggests a possible upside of 49.7% from the stock's current price.
View analysts price targets for AVDL
or view top-rated stocks among Wall Street analysts.

How have AVDL shares performed in 2022?

Avadel Pharmaceuticals' stock was trading at $8.08 at the beginning of the year. Since then, AVDL shares have decreased by 15.0% and is now trading at $6.87.
View the best growth stocks for 2022 here
.

When is Avadel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AVDL earnings forecast
.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) released its quarterly earnings data on Tuesday, August, 9th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.60. During the same period last year, the business posted ($0.33) EPS.

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Wealth Effects LLC (4.38%), Renaissance Technologies LLC (1.45%), Modera Wealth Management LLC (0.72%), Knott David M Jr (0.38%), Millennium Management LLC (0.36%) and State Street Corp (0.29%). Insiders that own company stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish, Sandra L Hatten and Thomas S Mchugh.
View institutional ownership trends
.

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $6.87.

How much money does Avadel Pharmaceuticals make?

Avadel Pharmaceuticals (NASDAQ:AVDL) has a market capitalization of $405.60 million and generates $22.33 million in revenue each year. The company earns $-77,330,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.

When was Avadel Pharmaceuticals founded?

Avadel Pharmaceuticals was founded in 2015.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The official website for the company is www.avadel.com. The company can be reached via phone at (531) 485-1200, via email at investors@avadel.com, or via fax at 353-1526-1077.

This page (NASDAQ:AVDL) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.